Boston Scientific Corporation (BSX)
-NYSE 9.28 
0.05(0.49%) 11:01AM EDT - Nasdaq Real Time Price
| Prev Close: | 9.23 |
|---|
| Open: | 9.20 |
|---|
| Bid: | 9.25 x 18900 |
|---|
| Ask: | 9.26 x 18900 |
|---|
| 1y Target Est: | 8.37 |
|---|
| Beta: | 1.24 |
|---|
| Next Earnings Date: | 24-Jul-13 |
|---|
| Day's Range: | 9.15 - 9.31 |
|---|
| 52wk Range: | 4.79 - 9.39 |
|---|
| Volume: | 8,099,509 |
|---|
| Avg Vol (3m): | 18,694,700 |
|---|
| Market Cap: | 12.53B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -3.28 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Boston Scientific says Lotus system met primary performance endpoint in trialtheflyonthewall.com(Wed 10:44AM EDT)
- Boston Scientific Reports Lotus™ Valve System Met Primary Performance Endpoint in REPRISE II TrialPR Newswire(Wed 10:40AM EDT)
- Boston Scientific Promus PREMIER™ And SYNERGY™ Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy DataPR Newswire(Wed 9:12AM EDT)
- Medtronic Beats Earnings, Results StrongerZacks(Wed 9:10AM EDT)
- 4 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, May 21)
- What's Behind Medtronic's 5% Pop?at Motley Fool(Tue, May 21)
- InPlay: Boston Scientific long term data demonstrate bronchial thermoplasty treatment benefits persist out to five years in patients with severe asthmaBriefing.com(Tue, May 21)
- Boston Scientific Long Term Data Demonstrate Bronchial Thermoplasty Treatment Benefits Persist Out to Five Years in Patients with Severe AsthmaPR Newswire(Tue, May 21)
- American Society Of Clinical Oncology Abstracts Point To Potential Profitsat Seeking Alpha(Tue, May 21)
- Insiders Are Buying These Stocks Nowat Motley Fool(Tue, May 21)
- Medtronic’s Heart Rhythm Devices Show Signs of Growthat Bloomberg(Tue, May 21)
- OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedingsPR Newswire(Tue, May 21)
- Boston Scientific Inc. (BSX): Today's Featured Health Services Winnerat TheStreet(Mon, May 20)
- July Options Now Available For Boston Scientificat Forbes(Mon, May 20)
- 1 Pioneering Device to Jump-Start the Cardiovascular Industryat Motley Fool(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 19.69 |
|---|
| P/S (ttm): | 1.74 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.41 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.10 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | 2.31 |
|---|
Business Summary
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. The company offers interventional cardiology products, including coronary stent systems used in the tre...
View More